Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-06-13
2011-12-06
Maier, Leigh (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S249000, C514S250000
Reexamination Certificate
active
08071557
ABSTRACT:
This disclosure relates generally to methods and pharmaceutical compositions useful in treating pulmonary hypertension. In one embodiment, for example, the disclosure provides a method for treating pulmonary hypertension comprising administering a therapeutically effective dose of a carbonic anhydrase inhibitor to a patient in need of treatment. The disclosure finds utility in the fields of medicine and pharmacology.
REFERENCES:
patent: 5242391 (1993-09-01), Place et al.
patent: 5474535 (1995-12-01), Place et al.
patent: 5773020 (1998-06-01), Place et al.
patent: 6656935 (2003-12-01), Yamada et al.
patent: WO0076493 (2000-12-01), None
patent: WO 2005/089766 (2005-09-01), None
patent: WO2006063078 (2006-06-01), None
patent: 2007/084290 (2007-07-01), None
patent: WO2008060963 (2008-05-01), None
Weber, M. “Topiramate for obstructive sleep apnea . . . ” Am. J. Psychiatry (2002) vol. 159, No. 5, pp. 872-873.
Olson, A. et al “The obesity hypoventilation syndrome” Am. J. Med. (2005) vol. 118, 948-956.
Runo, J. et al “Primary pulmonary hypertension” The Lancet (2003) vol. 361, pp. 1533-1544.
Barbera, J. et al “Pulmonary hypertension in chronic obstructive pumonary disease” Eur. Respir. J. (2003) vol. 21, pp. 892-905.
Moraes, D. et al “Secondary pulmonary hypertension . . . ” Circulation (2000) vol. 102, pp. 1718-1723.
Hohne, C. et al “Pulmonary vasodilation by acetazolamide during hypoxia . . . ” Am. J. Physiol. Lung Cell. Mol. Physiol. (2007) vol. 292, pp. L178-L184.
Humpl, T. et al “Beneficial effect of oral sildenafil therapy . . . ” Circulation (2005) vol. 111, pp. 3274-3280.
Affuso, F. et al “Tadalafil improves quality of life . . . ” Int. J. Cardiol. (2006) vol. 108, pp. 429-431.
Lahav, M. et al “Intermittent administration of furosemide . . . ” Chest (1992) vol. 102, pp. 725-731.
Nieminen, M. et al “Executive summary of the guidelines . . . ” Eur. Heart J. (2005) vol. 26, pp. 384-416.
International Preliminary Report on Patentability, Application No. PCT/US2008/006850, Mail Date: Dec. 30, 2009.
Najarian Thomas
Peterson Craig
Tam Peter Y.
Wilson Leland F.
Elrifi Ivor R.
Maier Leigh
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Pavao Matthew
Vivus Inc.
LandOfFree
Treatment of pulmonary hypertension with carbonic anhydrase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of pulmonary hypertension with carbonic anhydrase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of pulmonary hypertension with carbonic anhydrase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4299814